Article

Identification of a small-molecule entry inhibitor for filoviruses.

Microbiotix, Inc., One Innovation Drive, Worcester, MA 01605, USA.
Journal of Virology (Impact Factor: 5.08). 01/2011; 85(7):3106-19. DOI: 10.1128/JVI.01456-10
Source: PubMed

ABSTRACT Ebola virus (EBOV) causes severe hemorrhagic fever, for which therapeutic options are not available. Preventing the entry of EBOV into host cells is an attractive antiviral strategy, which has been validated for HIV by the FDA approval of the anti-HIV drug enfuvirtide. To identify inhibitors of EBOV entry, the EBOV envelope glycoprotein (EBOV-GP) gene was used to generate pseudotype viruses for screening of chemical libraries. A benzodiazepine derivative (compound 7) was identified from a high-throughput screen (HTS) of small-molecule compound libraries utilizing the pseudotype virus. Compound 7 was validated as an inhibitor of infectious EBOV and Marburg virus (MARV) in cell-based assays, with 50% inhibitory concentrations (IC(50)s) of 10 μM and 12 μM, respectively. Time-of-addition and binding studies suggested that compound 7 binds to EBOV-GP at an early stage during EBOV infection. Preliminary Schrödinger SiteMap calculations, using a published EBOV-GP crystal structure in its prefusion conformation, suggested a hydrophobic pocket at or near the GP1 and GP2 interface as a suitable site for compound 7 binding. This prediction was supported by mutational analysis implying that residues Asn69, Leu70, Leu184, Ile185, Leu186, Lys190, and Lys191 are critical for the binding of compound 7 and its analogs with EBOV-GP. We hypothesize that compound 7 binds to this hydrophobic pocket and as a consequence inhibits EBOV infection of cells, but the details of the mechanism remain to be determined. In summary, we have identified a novel series of benzodiazepine compounds that are suitable for optimization as potential inhibitors of filoviral infection.

0 Bookmarks
 · 
121 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Influenza viruses are a major public health threat worldwide and options for antiviral therapy are limited by the emergence of drug-resistant virus strains. The influenza glycoprotein hemagglutinin (HA) plays critical roles in the early stage of virus infection, including receptor binding and membrane fusion making it a potential target for the development of anti-influenza drugs. Using pseudotype virus based high throughput screens, we have identified several new small molecules capable of inhibiting influenza virus entry. We prioritized two novel inhibitors, MBX2329 and MBX2546, with aminoalkyl phenol ether and sulfonamide scaffolds respectively, that specifically inhibit HA-mediated viral entry. The two compounds (a) are potent (IC50 = 0.3-5.9 μM), (b) are selective (CC50 >100 μM) with selectivity index (SI) values >20-200 for different influenza strains, (c) inhibit a wide spectrum of influenza A virus that includes the 2009 pandemic influenza A/H1N1/2009, highly pathogenic avian influenza (HPAI) A/H5N1, and oseltamivir resistant A/H1N1 strains, (d) exhibit large volumes of synergy with oseltamivir (36-331 μM2 with 95% confidence) and (e) have chemically tractable structures. Mechanism of action studies suggest that both MBX2329 and MBX2546 bind to HA in a non-overlapping manner. Additional results from HA-mediated hemolysis of chicken red blood cells (cRBCs), competition assay with MAb C179 and mutational analysis suggest that the compounds bind in the stem region of the HA trimer and inhibit HA mediated fusion. Therefore, MBX2329 and MBX2546 represent new starting points for chemical optimization and have the potential to provide valuable future therapeutic options and research tools to study the HA mediated entry process.
    Journal of Virology 11/2013; · 5.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ebola is a highly virulent pathogen causing severe hemorrhagic fever with a high case fatality rate in humans and non-human primates (NHPs). Although safe and effective vaccines or other medicinal agents to block Ebola infection are currently unavailable, a significant effort has been put forth to identify several promising candidates for the treatment and prevention of Ebola hemorrhagic fever. Among these, recombinant adenovirus-based vectors have been identified as potent vaccine candidates, with some affording both pre- and post-exposure protection from the virus. Recently, Investigational New Drug (IND) applications have been approved by the US Food and Drug Administration (FDA) and phase I clinical trials have been initiated for two small-molecule therapeutics: anti-sense phosphorodiamidate morpholino oligomers (PMOs: AVI-6002, AVI-6003) and lipid nanoparticle/small interfering RNA (LNP/siRNA: TKM-Ebola). These potential alternatives to vector-based vaccines require multiple doses to achieve therapeutic efficacy, which is not ideal with regard to patient compliance and outbreak scenarios. These concerns have fueled a quest for even better vaccination and treatment strategies. Here, we summarize recent advances in vaccines or post-exposure therapeutics for prevention of Ebola hemorrhagic fever. The utility of novel pharmaceutical approaches to refine and overcome barriers associated with the most promising therapeutic platforms are also discussed.
    BioDrugs 06/2013; · 2.12 Impact Factor
  • Source

Full-text (2 Sources)

View
12 Downloads
Available from
May 31, 2014